Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
0.656
+0.003 (0.49%)
At close: Apr 28, 2026, 4:00 PM EDT
0.654
-0.002 (-0.35%)
After-hours: Apr 28, 2026, 7:10 PM EDT
Fractyl Health Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Fractyl Health stock have an average target of 5.40, with a low estimate of 2.00 and a high estimate of 8.00. The average target predicts an increase of 722.79% from the current stock price of 0.66.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Fractyl Health stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +1,118.95% | Apr 24, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +1,118.95% | Mar 26, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +204.74% | Jan 30, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +1,118.95% | Dec 2, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $8 | Strong Buy | Maintains | $6 → $8 | +1,118.95% | Nov 21, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
18.22M
EPS This Year
-0.69
from -1.86
EPS Next Year
-0.60
from -0.69
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | n/a | 75.0M | ||||
| Avg | n/a | 18.2M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -0.61 | -0.40 | ||||
| Avg | -0.69 | -0.60 | ||||
| Low | -0.78 | -0.79 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.